Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Bull Horn Holdings (BHSEU)
New Beginnings Acquisition (NBA.U)
CONX (CONXU)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Cerberus Telecom Acquisition (CTACU)
Upcoming IPO
OTR Acquisition (OTRAU)
Natural Order Acquisition (NOACU)
Priced IPO
Allegro MicroSystems, Inc. (ALGM)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Absolute Software (ABST)
EQT Corporation (EQT)
Foghorn Therapeutics Inc. (FHTX)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Datto Holding Corp. (MSP)
MingZhu Logistics Holdings (YGMZ)
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
More companies

Pulmonx Corporation (LUNG)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Their solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. They estimate their solution currently addresses approximately 500,000 patients in the United States and 700,000 patients in select international markets, which represents a global market opportunity of approximately $12 billion. They have a compelling body of clinical evidence with over 100 scientific articles published regarding the clinical benefits of Zephyr Valves, including in The New England Journal of Medicine, The Lancet and the American Journal of Respiratory and Critical Care Medicine. Multiple randomized controlled clinical trials have demonstrated that patients selected with the Chartis System and successfully treated with Zephyr Valves have shown statistically and clinically significant improvements in lung function, exercise capacity and quality of life compared to medical management alone.
Industry
Surgical & Medical Instruments & Apparatus
CEO CFO
Steven C. Eror Mark V. Anderson
Employees Founded
202 1995

Contacts

Address: 700 Chesapeake Drive Redwood City, California 94063

Telephone: 1-650-364-0400

Web page: http://www.prolunginc.com

IPO information

Expected Date 10/1/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range $7.00-$8.00
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $593.7
Revenues (MM) $31.7
Net Income (Loss) (MM) $-37.7

Voting

What do you think will happen with the LUNG share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 0.9
Shares Revised (MM) 10
Expected offer amount (MM) $100.5
Realized offer amount(MM) $190
Underwriters
BofA Securities/ Morgan Stanley
CO-Managers
Stifel/ Wells Fargo Securities/ Canaccord Genuity

Sector: Healthcare

Tweets about $LUNG

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats